Skip to main content
NewslettersWatchlist

Arrowhead Pharma(ARWR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low22.66
Day High23.84
Open:22.72
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
Motley Fool
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
Business Wire
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
Motley Fool
Is Arrowhead Pharmaceuticals a Buy Now?
Business Wire
Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
Motley Fool
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Business Wire
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Business Wire
Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
MarketBeat
Want Diversified Upside in Biotechnology? Check out LABU
Business Wire
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
Business Wire
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
Business Wire
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Business Wire
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
Business Wire
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Business Wire
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
Business Wire
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Business Wire
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
Baystreet
Banks’ Quarterly Numbers in Focus Next Week
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
Business Wire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Business Wire
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Profile

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.